RU
Address
220006, Minsk, Leningradskaya Str. 6, office 2
Tel.: +375 17 363-88-92
E-mail: medjournal@bsmu.by

Механизмы и оценка аллореактивности при трансплантации печени

Д. Ю. Ефимов, А. В. Носик, Г. В. Жук, С. В. Коротков, А. М. Дзядзько, А. Е. Щерба, О. О. Руммо РНПЦ трансплантации органов и тканей на базе УЗ «9-я городская клиническая больница»
2016 №1 | Лекции
Аннотация
Список литературы
Скачать полнотекстовую статью
В данной статье проанализирован опыт ведущих трансплант-центров в диагностике, лечении и оценке риска данного осложнения. Изложена современная концепция патогенеза иммунологического конфликта между реципиентом и печеночным графтом. Очерчены основные методы мониторинга иммунологического статуса реципиента и перспективы развития данного направления.
Ключевые слова:
трансплантация печени, иммунный ответ, иммунологическая реактивность реципиента
Mechanisms and assessment of alloreactivity after liver transplantation

In this article the experience of the leading transplant centers in the diagnosis, treatment and evaluation of the risk of this complication has been analyzed. It describes the modern concept of the pathogenesis of immunological conflict between the recipient and the liver graft. It outlines the basic methods of monitoring the recipient’s immunological status and prospects of development of this scientifical direction.

Keywords
liver transplantation, immune response, immunologic reactivity of recipient
  • 1. Shaked, A., Ghobrial R. M., Merion R. M. et al. Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation. Am. J. Transplant. 2009;9(2):301–308.
  • 2. Snover, D. C., Sibley R. K., Freese D. K. et al. Orthotopic liver transplantation: a pathological study of 63 serial liver biopsies from 17 patients with special reference to the diagnostic features and natural history of rejection. Hepatology. 1984;4(6):1212–1222.
  • 3. Ray, R. A., Lewin K. J., Colonna J. et al. The role of liver biopsy in evaluating acute allograft dysfunction following liver transplantation: a clinical histologic correlation of 34 liver transplants. Hum Pathol. 1988;19(7):835–848.
  • 4. Ascher, N. L., Stock P. G., Bumgardner G. L. et al. Infection and rejection of primary hepatic transplant in 93 consecutive patients treated with triple immunosuppressive therapy. Surg Gynecol Obstet. 1988;167(6):474–484.
  • 5. Fisher, L. R., Henley K. S., Lucey M. R. Acute cellular rejection after liver transplantation: variability, morbidity, and mortality. Liver Transpl Surg. 1995;1(1):10–15.
  • 6. Demetris, A. J., Ruppert K., Dvorchik I. et al. Real-time monitoring of acute liver-allograft rejection using the Banff schema. Transplantation. 2002;74(9):1290–1296.
  • 7. Seiler, C. A., Renner E. L., Czerniak A. et al. Early acute cellular rejection: no effect on late hepatic allograft function in man. Transpl Int. 1999;12(3):195–201.
  • 8. Dousset, B., Conti F., Cherruau B. et al. Is acute rejection deleterious to long-term liver allograft function? J. Hepatol. 1998; 29(4):660–668.
  • 9. Demetris, A. J., Murase N., Ye Q. et al. Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am. J. Pathol. 1997;150(2):563–578.
  • 10. Vierling, J. M. Immunology of acute and chronic hepatic allograft rejection. Liver Transpl Surg. 1999;5(4 suppl 1):S1–S20.
  • 11. Germain, R. N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell. 1994;76(2):287–299.
  • 12. Neuberger, J., Adams D. What is the significance of acute liver allograft rejection? Journal of Hepatology. 1998;29:143.
  • 13. Adams, A. B., Williams M. A., Jones T. R. et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J. Clin. Invest. 2003;111(12):1887–1895.
  • 14. Hubscher, S. G. Histological findings in liver allograft rejection–new insights into the pathogenesis of hepatocellular damage in liver allografts. Histopathology. 1991;18(4):377–383.
  • 15. Martinez, O. M., Burke E. C., Alan T. J., Ascher N. L. Allogeneic hepatocytes stimulate the production of immunoregulatory molecules in mixed lymphocyte hepatocyte cultures. Transplant Proc. 1991;23(1 Pt 1):805–806.
  • 16. Perrella, O., Sbreglia C., Arenga G. et al. Acute rejection after liver transplantation: Is there a specific immunological pattern? Transplant Proc. 2006;38(10):3594–3596.
  • 17. Sun, Z., Wada T., Maemura K. et al. Hepatic allograftderived Kupffer cells regulate T cell response in rats. Liver Transpl. 2003;9 (5):489–497.
  • 18. Li, J., Yang Y., Inoue H. et al. The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines: its regulation by interferon gamma and interleukin-10. Cancer Immunol Immunother. 1996;43(4):213–219.
  • 19. Chen, Y., Chen J., Liu Z. et al. Relationship between TH1/TH2 cytokines and immune tolerance in liver transplantation in rats. Transplant Proc. 2008;40(8):2691–2695.
  • 20. Bumgardner, G. L., Chen S., Almond P. S. et al. Cell subsets responding to purified hepatocytes and evidence of indirect recognition of hepatocyte major histocompatibility complex class I antigen. II. In vitro-generated “memory” cells to class I+ class II– hepatocytes. Transplantation. 1992;53(4):863–868.
  • 21. Ramos, H. C., Reyes J., Abu-Elmagd K. et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation. 1995;59(2):212–217.
  • 22. Koshiba, T., Li Y., Takemura M. et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol. 2007;17(2): 94–97.
  • 23. Sakaguchi, S., Sakaguchi N., Asano M. et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of selftolerance causes various autoimmune diseases. J. Immunol. 1995;155(3):1151–1164.
  • 24. Gavin, M. A., Rasmussen J. P., Fontenot J. D. et al. Foxp3 dependent programme of regulatory T-cell differentiation. Nature. 2007;445(7129):771–775.
  • 25. Li, Y., Zhao X., Cheng D. et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation. 2008;86(12):1837–1843.
  • 26. Xie, L., Ichimaru N., Morita M. et al. Identification of a novel biomarker gene set with sensitivity and specificity for distinguishing between allograft rejection and tolerance. Liver Transpl. 2012; 18(4):444–454.
  • 27. Steinhoff, G., Wonigeit K., Pichlmayr R. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation. 1988;45(2):394–401.
  • 28. Burke, E. C., Martinez O. M., Freise C. E. et al. MHC expression on human hepatocytes before and after isolation. Transplant Proc. 1991;23(1 Pt 2):1428–1429.
  • 29. So, S. K., Platt J. L., Ascher N. L., Snover D. C. Increased expression of class I major histocompatibility complex antigens on hepatocytes in rejecting human liver allografts. Transplantation. 1987;43(1):79–85.
  • 30. Suehiro, T., Shimada M., Kishikawa K. et al. Influence of HLA compatibility and lymphocyte cross-matching on acute cellular rejection following living donor adult liver transplantation. Liver Int. 2005;25(6):1182–1188.
  • 31. Kasahara, M., Kiuchi T., Uryuhara K. et al. Role of HLA compatibility in pediatric living-related liver transplantation. Transplantation. 2002;74(8):1175–1180.
  • 32. Muro, M., Lopez-Alvarez M. R., Campillo J. A. et al. Influence of human leukocyte antigen mismatching on rejection development and allograft survival in liver transplantation: is the relevance of HLA-A locus matching being underestimated? Transpl Immunol. 2012;26(2-3):88–93.
  • 33. Lan, X., Zhang M. M., Pu C. L. et al. Impact of human leukocyte antigen mismatching on outcomes of liver transplantation: a meta-analysis. World J Gastroenterol. 2010;16(27):3457–3464.
  • 34. Smith, T. P., Presson T. L., Heneghan M. A., Ryan J. M. Transjugular biopsy of the liver in pediatric and adult patients using an 18-gauge automated core biopsy needle: a retrospective review of 410 consecutive procedures. AJR Am. J. Roentgenol. 2003; 180(1):167–172.
  • 35. Miraglia, R., Maruzzelli L., Minervini M. I. et al. Transjugular liver biopsy in liver transplant patients using an 18-gauge automated core biopsy needle. Eur. J. Radiol. 2011;80(3):e269–e272.
  • 36. Post, D. J., Douglas D. D., Mulligan D. C. Immunosuppression in liver transplantation. Liver Transpl 2005; 11: 1307–1314.
  • 37. Levitsky, J. Next level of immunosuppression: drug/immune monitoring. Liver Transpl2011; 17 Suppl 3: S60–S65.
  • 38. Sood, S. et al. Immune monitoring post liver transplant calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562–2575.
  • 39. Rovira, P., Mascarell L., Truffa-Bachi P. The impact of immunosuppressive drugs on the analysis of T cell activation. Curr Med Chem2000; 7: 673–692.
  • 40. Wieland, E. et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit. 2010; 32: 560–572.
  • 41. Zahn, A. et al. Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: the first clinical trial in liver allograft recipients. Liver Transpl 2011; 17: 466–473.
  • 42. Sawitzki, B., Schlickeiser S., Reinke P., Volk H. D. Monitoring tolerance and rejection in organ transplant recipients. Biomarkers. 2011; 16 Suppl 1: S42–S50.
  • 43. Israeli, M., Klein T., Brandhorst G., Oellerich M. Confronting the challenge: individualized immune monitoring after organ transplantation using the cellular immune function assay. Clin. Chim. Acta. 2012; 413: 1374–1378.
  • 44. Levitsky, J. Operational tolerance: past lessons and future prospects. Liver Transpl 2011; 17: 222-232
  • 45. Chung, S. W., Yoshida E. M., Cattral M. S., Hu Y., Gorczynski R. M. Donor-specific stimulation of peripheral blood mononuclear cells from recipients of orthotopic liver transplants is associated, in the absence of rejection, with type-2 cytokine production. Immunol Lett 1998; 63: 91–96.
  • 46. Tanaka, Y., Tashiro H., Onoe T., Ide K., Ishiyama K., Ohdan H. Optimization of immunosuppressive therapy based on a multiparametric mixed lymphocyte reaction assay reduces infectious complications and mortality in living donor liver transplant recipients. Transplant Proc 2012; 44: 555–559.
  • 47. Tanaka, Y., Ohdan H., Onoe T., Mitsuta H., Tashiro H., Itamoto T., Asahara T. Low incidence of acute rejection after living donor liver transplantation: immunologic analyses by mixed lymphocyte reaction using a carboxyfluorescein diacetate succinimidyl ester labeling technique. Transplantation2005; 79: 1262–1267.
  • 48. Hricik, D. E. et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferongamma independently predicts renal function in kidney transplant recipients. Am J Transplant2003; 3: 878–884.
  • 49. Näther, B. J. et al. Modified ELISPOT technique--highly significant inverse correlation of post-Tx donor-reactive IFNgammaproducing cell frequencies with 6 and 12 months graft function in kidney transplant recipients. Transpl Immunol 2006; 16: 232–237.
  • 50. Reding, R., Gras J., Truong D. Q., Wieërs G., Latinne D. The immunological monitoring of alloreactive responses in liver transplant recipients: a review. Liver Transpl2006; 12: 373–383.
  • 51. Mineo, D., Ricordi C. Chimerism and liver transplant tolerance. J Hepatol 2008; 49: 478–480.